Business
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)" (hereinafter referred to as the "Guideline (Draft)") on May 21, recommending the etiological treatment with a 9-month course of NEFECON® for
About this update from Everest Medicines Ltd.
[{"type":"text","content":"SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)" (hereinafter referred to as the "Guideline (Draft)") on May 21, recommending the etiological treatment with a 9-month course of NEFECON® for all primary immunoglobulin A nephropathy (IgAN) patients who are at risk for disease progression, irrespective of proteinuria levels (2B).","length":728,"tagName":"p"},{"type":"text","content":"The Guideline (Draft) was presented by Professor Hong Zhang and Professor Jicheng Lv from Peking University First Hospital, during the IgA Nephropathy Forum and IIgANN-China Annual Meeting. It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the cause, Treat early, Treat comprehensively.","length":433,"tagName":"p"},{"type":"text","content":"The Guideline (Draft) recommends that patients with proteinuria ≥ 0.5g/day (or equivalent levels) undergo a renal biopsy and initiate treatment. The treatment goal is to slow the estimated glomerular filtration rate (eGFR) loss to less than 1 ml/min per year. In addition to the two core indicators of proteinuria and eGFR, the Guideline (Draft) also emphasizes routine monitoring of hematuria.","length":394,"tagName":"p"},{"type":"text","content":"For the first time, the guideline introduces interventions targeting immune-mediated injury, particularly the formation of pathogenic IgA (Gd-IgA1), a key driver of pathogenesis to IgAN. For patients at risk of disease progression, the guideline proposes addressing both symptoms of renal function decline, and initiating therapies targeting immune-mediated injury and CKD progression. NEFECON® is recommended as the preferred treatment to reduce Gd-IgA1. Once short-term treatment goals, namely proteinuria remission (defined as proteinuria < 0.5 g/day, ideally < 0.3 g/day) and stable renal function, are achieved, low-dose maintenance or ...